Brief: Metavia Doses The First Patient In Higher-Dose Phase 1 Study Of Da-1726, Its Glp-1 And Glucagon Dual Agonist For The Treatment Of Obesity
10/04/2026 13:39
April 10 (Reuters) - MetaVia Inc MTVA.O: METAVIA DOSES THE FIRST PATIENT IN HIGHER-DOSE PHASE 1 STUDY OF DA-1726, ITS GLP-1 AND GLUCAGON DUAL AGONIST FOR THE TREATMENT OF OBESITY METAVIA INC - DATA FROM PHASE 1 PART 3 TRIAL EXPECTED IN Q4 2026 Source text: ID:nPn5vJC66a Further company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise